Corporate Profile

Founded in 2007, Starling Oncology, Inc. (Nasdaq: "STLN" effective August 4, 2026, replacing its previous ticker symbol “TOI.”) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with leading oncology organizations. With more than 400 employed and network clinicians and more than 100 clinics and network locations across five states and growing, Starling Oncology is coordinating cancer care for the better.

Minimum 15 minutes delayed. Source: LSEG

SEC Filings

Report of unscheduled material events or corporate event
8-K
Statement of changes in beneficial ownership of securities
4
Statement of changes in beneficial ownership of securities
4